ALNY Kevin Joseph Fitzgerald sells $469K worth of shares
Mar 06, 2025, 5:33 AM
0.00%
What does ALNY do
Alnylam Pharmaceuticals, based in Cambridge, Massachusetts, specializes in mRNA cell therapies for autoimmune diseases, with its lead candidate Descartes-08 in Phase IIb trials for generalized myasthenia gravis. The company also develops Descartes-15 and Descartes-33, targeting B cell maturation antigen and autoimmune drivers, respectively.
Kevin Joseph Fitzgerald sold 1,911 shares of ALNY on 3 March at $245.30 per share, worth a total of $469K. They now own 16,052 ALNY shares, or a 12% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
